Fiera Capital Corp Has $58.80 Million Holdings in Zoetis Inc. $ZTS

Fiera Capital Corp decreased its stake in Zoetis Inc. (NYSE:ZTS) by 2.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 401,887 shares of the company’s stock after selling 8,674 shares during the quarter. Fiera Capital Corp owned approximately 0.09% of Zoetis worth $58,804,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ZTS. Savvy Advisors Inc. increased its holdings in Zoetis by 54.0% during the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock worth $495,000 after purchasing an additional 1,114 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after purchasing an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its position in shares of Zoetis by 6.5% during the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after buying an additional 18,040 shares during the period. Ninety One UK Ltd grew its holdings in shares of Zoetis by 19.6% during the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after buying an additional 183,686 shares in the last quarter. Finally, Quilter Plc grew its holdings in shares of Zoetis by 10.2% during the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after buying an additional 40,615 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of recent research reports. JPMorgan Chase & Co. reduced their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. KeyCorp started coverage on shares of Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating on the stock. Stifel Nicolaus decreased their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Piper Sandler reiterated a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Finally, Barclays began coverage on shares of Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Stock Performance

Shares of ZTS opened at $127.12 on Friday. The company has a market cap of $53.66 billion, a PE ratio of 21.12, a price-to-earnings-growth ratio of 1.97 and a beta of 0.96. The firm has a 50-day moving average of $125.20 and a 200-day moving average of $134.96. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.